IRIS
DE LUCA, Giovanna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.368
EU - Europa 2.093
AS - Asia 971
Continente sconosciuto - Info sul continente non disponibili 9
AF - Africa 1
SA - Sud America 1
Totale 5.443
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.364
CN - Cina 498
UA - Ucraina 448
IE - Irlanda 435
GB - Regno Unito 332
TR - Turchia 329
SE - Svezia 276
IT - Italia 182
FR - Francia 170
DE - Germania 137
IN - India 91
FI - Finlandia 89
VN - Vietnam 33
IR - Iran 10
EU - Europa 9
BE - Belgio 8
RU - Federazione Russa 7
IL - Israele 5
GR - Grecia 4
CA - Canada 3
AM - Armenia 1
AT - Austria 1
BG - Bulgaria 1
CL - Cile 1
DK - Danimarca 1
EG - Egitto 1
HK - Hong Kong 1
IM - Isola di Man 1
KR - Corea 1
MX - Messico 1
PH - Filippine 1
RO - Romania 1
SG - Singapore 1
Totale 5.443
Salva come PNG Salva come JPEG
Città #
Jacksonville 511
Chandler 508
Dublin 431
Southend 258
Izmir 192
Princeton 188
Nanjing 151
Wilmington 128
Ashburn 106
Beijing 94
Cambridge 84
Dearborn 84
Nanchang 58
Ann Arbor 51
Woodbridge 51
Altamura 45
New York 42
Chieti 34
Dong Ket 33
Jiaxing 29
Houston 26
Shenyang 25
Norwalk 24
Boardman 20
Grevenbroich 19
Kunming 19
Tianjin 19
Los Angeles 17
Hebei 16
Washington 15
Changsha 12
Hangzhou 12
Leawood 12
San Mateo 12
Ardabil 10
Augusta 9
Cedar Knolls 9
Jinan 9
Torino 9
Brussels 7
Campobasso 7
Helsinki 7
Lanzhou 7
Monmouth Junction 7
Falls Church 6
Guangzhou 6
London 6
Ningbo 6
Changchun 5
Hanover 5
Orange 5
Pescara 5
Taizhou 5
Zhengzhou 5
San Vito Chietino 4
Borgomanero 3
Florence 3
Mumbai 3
Oxford 3
Pianella 3
Tappahannock 3
Teramo 3
Toronto 3
Walnut 3
Bangalore 2
Benevento 2
Cedar Lake 2
Düsseldorf 2
Frankfurt am Main 2
Fuzhou 2
Hefei 2
Isernia 2
L’Aquila 2
Milan 2
Naples 2
Phoenix 2
Rome 2
Seattle 2
Shanghai 2
Somerville 2
Stockholm 2
Andover 1
Antwerp 1
Archi 1
Auburn Hills 1
Basking Ridge 1
Berlin 1
Boston 1
Cairo 1
Candiolo 1
Central 1
Chengdu 1
Domusnovas 1
Douglas 1
Dragoni 1
Elk Grove Village 1
Fairfield 1
Gandhi Nagar 1
Glasgow 1
Haikou 1
Totale 3.545
Salva come PNG Salva come JPEG
Nome #
IL 13 in multiple sclerosis 113
Integrated Lipidomics and Metabolomics Analysis of Tears in Multiple Sclerosis: An Insight into Diagnostic Potential of Lacrimal Fluid 103
La funzione soppressoria è ridotta nella polineuropatia demielinizzante cronica infiammatoria (CIDP) 89
Lipidomic investigations for the characterization of circulating serum lipids in multiple sclerosis 88
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. 82
The Multiple Sclerosis Knowledge Questionnaire: a self administered instrument for recently diagnosed patients 81
Effect of TNF intraneural injection into the rat sciatic nerve 78
The Chieti experience with Interferon B1b (IFNB1b) during the first 2 years: side effects. 78
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis 78
Chemokine production by mononuclear cells from relapsing-remitting multiple sclerosis (RR-MS) patients 78
Alzheimer patients treated with an AchE inhibitor show higher IL-4 and lower IL-1β levels and expression in peripheral blood mononuclear cells 78
Effetti sinergici della terapia con interferone-beta sulla attivazione, adesione ed apoptosi linfocitaria nella sclerosi multipla esacerbante/remittente 78
Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. 77
Increasing age at disability milestones among MS patients in the MSBase Registry 76
Dysimmune demyelinating polyneuropathies: expression of adhesion molecules in sural nerves and changes in cellular immunity (suppressor cell function and cytokine mRNA expression) induced by treatment (progetto presentato a Telethon) 75
Convulsive status epilepticus due to new encephalic demyelinating lesions in multiple sclerosis 75
Rantes Levels and mRNA Expression in Relapsing-Remitting Multiple Sclerosis (RR-MS): Effect of interferon Beta 1b (IFNBeta 1b) Treatment 75
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone 74
Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy. 74
The Chieti Experience with interferon B1b (IFNB1b) during the first 2 years: Efficacy 73
Chemokines are Modulated by Interferon beta 1B (IFNT-Beta IB) in Relapsing-Remitting Multiple Sclerosis (RR-MS) 72
Real-life impact of early interferon beta therapy in relapsing multiple sclerosis 72
Anti-glycolipid and anti-tubulin antibodies in chronic inflammatory demyelinating polyneuropathy 71
Rantes and MCP-1 Secretion by Mononuclear Cells of Patients with Nultiple Sclerosis 70
Interferon β1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis 70
Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: a prospective study 70
Serum soluble adhesion molecules and proinflammatory cytokines are not increased in chronic inflammatory demyelinating polyneuropathy 68
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 68
OXIDATIVE MODIFICATIONS OF CEREBRAL TRANSTHYRETIN ARE ASSOCIATED WITH MULTIPLE SCLEROSIS 68
Nail loss after teriflunomide treatment: a new potential adverse event 68
Shared T Cell Receptor Usage of Cerebrospinal Fluid Cells in Familial Multiple Sclerosis da: X° National A.I.N.I. Congress Association Italiana Neuroimmunologia - Florence, Italy, November 15/16,1999 67
MCP-1 expression and secretion in adherent monocyte cultures from multiple sclerosis patients treated with interferon beta-1b 67
Breastfeeding is not related to postpartum relapses in multiple sclerosis. 67
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 66
Acetylcholine in multiple sclerosis: possible involvement in the modulation of the immune response and in oligodendrocyte recruitment. 66
Anti-JCV serostatus, index value and clinical features in patients affected by multiple sclerosis. 66
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy. 65
Interferon beta normalizes suppressor cell function in dysimmune neuropathies. 65
Livelli sierici e liquorali di IL13 nella Sclerosi Multipla 64
Effetti sinergici della terapia con interferone-beta sulla attivazione. Adesione ed apoptosi linfocitaria nella sclerosi multipla esacerbante /remittente. (C22) 64
Patient adherence to and tolerability of self-administered interferon beta-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study 64
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. 64
Interferon beta1b: the Chieti experience 63
Effect of rhTNF-alpha injection into rat sciatic nerve 63
Prevalence of JC virus antibodies in human serum and seroconversion rate with first-generation and second generation ELISA: the novel assay improves specificity andsensitivity to detect anti-JC virus antibodies 63
Effects of IL10 on recombinant interferon-beta1b stimulated suppressor cell function in MS and controls subjects 62
Effect of rhTNF-a injection into rat sciatic nerve 62
Neuropsychological testing and quantitative electroencephalography: a search of neurophysiological markers of cognitive decline in multiple sclerosis 62
JCV-Ab serostatus in MS patients treated with Natalizumab 62
Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. 62
Multiphasic Adem or Multiple Sclerosis? Treatement implications. 60
A cross-sectional, multicentre study of the therapeutic management of multiple sclerosis relapses in Italy 60
Interferon beta normalizes suppressor cell function in dysimmune neuropathies 59
Suppressor cell function is decreased in chronic inflammatory demyelinating polyneuropathy 59
Mononeuropathy following subcutaneous interferon-β injection 59
CD1A and CD1E gene polymorphisms are associated withsusceptibility to multiple sclerosis 59
Treatment discontinuation issues in fingolimod treated patients: the Chieti experience. 59
rlFN-beta-1B stimulated suppressor cell function in multiple sclerosis: effects of anti-IL-10 monoclonal antibody 58
Interferone beta1b: bilancio su un gruppo di 30 pazienti 57
Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. 57
Interferon β 1b: The Chieti experience 57
IL-13 levels in serum and cerebro-spinal fluid of multiple sclerosis patients 56
A difficult pediatric case: ADEM evolving in multiple sclerosis complicated by progressive multifocal leukoencephalopathy after Natalizumab treatment. 56
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 55
Low dose oral methotrexate (MTX) in chronic progressive (CP) multiple sclerosis (MS) 55
Neuropsychological testing and event-related potentials: markers of cognitive impairment in patients with multiple sclerosis 53
Proteomic investigations on differential post-translational modification of transthyretin in multiple sclerosis. 53
A Multicentre italian study on efficacy and safety of Glatiramer Acetate in multiple sclerosis patients with allergic respiratory diseases 53
Effects of IFN-Beta on rantes and MCP-1 secretion by mononuclear cells frm patients with multiple sclerosis 53
Progressive multifocal leukoencephalopathy associated with natalizumab in paediatric multiple sclerosis 52
Evaluation of suppressor cell function in chronicn inflammatory demyelinating polyneuropathy (CIDP) 50
Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients. 49
Non-neuronal acetylcholine: a new modulator of immune responses in multiple sclerosis patients. 49
Interferon beta normalizes suppressor cell function in dysimmune neuropathies 48
Gestione degli effetti indesiderati della terapia con interferone beta nella sclerosi multipla 47
Relation between Pro-inflammatory Cytokines and Acetylcholine Levels in Relapsing-Remitting Multiple Sclerosis Patients 46
Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register 43
Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis 41
Spinal cord injury in a patient with multiple sclerosis (MS) with secondary hydromyelia 41
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs 41
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society 40
Modulation of the immune response in multiple sclerosis patients: effect of non-neuronal acetylcholine 34
Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study. 34
Plasma exchange and prednisone improve suppressor cell function in dysimmune neuropathies 32
Efficacy and safety of glatiramer acetate in multiple sclerosis patients with allergicrespiratory diseases. 31
Pregnancy and fetal outcomes after paternal exposure to disease modifying drugs for multiple sclerosis 30
Contribution of metabolomics to multiple sclerosis diagnosis, prognosis and treatment 29
Pregnancy And Fetal Outcomes After Paternal Exposure To Disease Modifying Drugs For Multiple Sclerosis (P4.157) 28
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 28
Epilepsy and multiple sclerosis: Clinical, radiological, electrophysiological and neuropsychological aspects 27
Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases 25
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 14
mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis 13
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 11
SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose 8
Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 3
Progressive multifocal leukoencephalopathy or severe multiple sclerosis relapse following COVID-19 vaccine: a diagnostic challenge 3
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 1
Totale 5.580
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.366
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.366
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019245 0 0 0 0 0 0 0 0 0 0 2 243
2019/20201.096 349 82 7 34 66 92 117 105 16 90 134 4
2020/2021616 86 0 91 1 37 123 1 2 80 68 58 69
2021/2022357 2 4 6 57 11 11 16 34 32 7 54 123
2022/20231.321 104 152 72 158 143 272 81 93 171 17 29 29
2023/2024599 46 30 38 16 37 225 145 30 0 31 1 0
Totale 5.580